SLC5A1 and chronic kidney disease: The dual SGLT1/2 inhibitor sotagliflozin was also evaluated in T2D with stage 3 CKD in a phase three trial, showing improved glycemic control and reduced albuminuria at 26 weeks, though sustained eGFR benefits at 52 weeks remained inconclusive (p > 0.05) [53].